Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
Sign Up to like & getrecommendations! Published in 2022 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noac099
Abstract: Abstract Background Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival (OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with tumors harboring an unmethylated MGMT promoter derive minimal benefit. The… read more here.
Keywords: unmethylated mgmt; phase iii; newly diagnosed; mgmt promoter ... See more keywords